Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07689851 | Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07621484 | HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 48 | Shanghai Changzheng HospitalOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07685704 | Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study | not yet recruiting | Phase 2 | 46 | Zhifeng Zhao, PhDOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05709574 | Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer | active not recruiting | Phase 2 | 11 | University of ArizonaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05836584 | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | active not recruiting | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06630130 | Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer | recruiting | Phase 2 | 100 | Jeeyun LeeOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07139951 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | enrolling by invitation | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07669740 | A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07658872 | Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | not yet recruiting | Phase 2 | 120 | Sichuan UniversityOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06365008 | Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer | not yet recruiting | Phase 2 | 27 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655661 | Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 52 | Ming LiuOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07143604 | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2(GAMBIT) | active not recruiting | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07655024 | TAIC FOLFOX for Locally Advanced G/GEJA(TFLAG) | recruiting | Phase 2 | 31 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06109467 | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer | active not recruiting | Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07638631 | Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer(DIAMC-GC) | not yet recruiting | Phase 2 | 30 | Chen LizhuOTHER_GOV | 0 | Jun 10, 2026 | clinicaltrials |
| NCT04739202 | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)(IMMUNOGAST) | completed | Phase 2 | 54 | Hospices Civils de LyonOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT04632459 | Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer | completed | Phase 2 | 26 | Samsung Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05379972 | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | completed | Phase 2 | 9 | University of Colorado, DenverOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06504732 | To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | recruiting | Phase 2 / Phase 3 | 574 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07621562 | Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07133490 | INTERACT Stomach-II | recruiting | Phase 2 | 55 | Erasmus Medical CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07610629 | Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer(RA-A-NP) | not yet recruiting | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT05977998 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07595523 | Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT06251973 | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06580574 | Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers | recruiting | Phase 2 | 34 | Peking UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05702229 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 163 | AstraZenecaINDUSTRY | 7 | May 14, 2026 | clinicaltrials |
| NCT07241715 | Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)(CONVERGENCE) | active not recruiting | Phase 2 / Phase 3 | 300 | National University Hospital, SingaporeOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT04923932 | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | completed | Phase 2 | 110 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT07511894 | Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer(BBNIGC) | not yet recruiting | Phase 2 | 33 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04736485 | Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)(GASPAR) | completed | Phase 2 | 67 | Centre Francois BaclesseOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2026source: clinicaltrials